Endocrine Abstracts

Introduction: Maturity onset diabetes of the young (MODY) is a group of monogenic, autosomal, dominant diseases characterized by a single genetic mutation that results in beta-cells disfunction with consequent hyperglycemia. It Accounts for 1-5% of all cases of diabetes. At the moment, optimal treatment has not been established and it relies on the individual response. A mutation of NEUROD1 gene, a transcription factor expressed by pancreatic and nervous tissues, has been foun...

Aim: The current focus for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) is lifestyle intervention with the aim of significant weight loss. NAFLD is tightly associated with type 2 diabetes (T2D) and obesity. In patients with T2D, glucose lowering agents that promote weight loss have shown a beneficial impact on NAFLD. However, it remains unclear as to whether glucose lowering can improve NALFD in patients with T2D, independent of weight loss.<p class="abstext"...

Introduction: Hemolytic-uremic syndrome (HUS) is a clinical condition characterized by nonimmune hemolytic anemia, thrombocytopenia and progressive kidney failure mediated by E.Coli Shiga-like toxin. In rare cases the inflammatory process may lead to beta-cell necrosis and, hence, overt diabetes mellitus. Post-HUS DM is characterized by severe insulin depletion and very high insulin sensitivity, making its therapeutic management particularly challenging....

Background and aims: There is evidence that new anti-diabetic drugs may limit liver disease progression, reduce liver fat and normalize serum aminotranferase levels in patients with NAFLD. We compared the effectiveness of new drug classes on liver fat in T2DM patients by means of surrogate markers.Materials and methods: In an observational retrospective study we analysed the 12-month time-courses of clinical and anthropometric data of T2DM cases treated ...

We retrospectively studied the effect on BMI and metabolic control (HbA1c within therapeutic targets) of structured lifestyle intervention associated with glucagon-like-1 receptor agonists (GLP-1RA) compared to GLP-1RA alone in patients with Type 2 diabetes (T2DM).Materials and method: The anthropometric and clinical data of 525 T2DM patients who started therapy with GLP-1RA were collected in a comprehensive database with follow-up of 24 months. Accordin...

Introduction: The relationship between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes is well-established. However, the precise impact of glucose control on the severity and progression of NAFLD remains largely unexplored. Currently, none of the non-invasive scoring systems used to assess NAFLD severity incorporate glucose control markers, such as glycated hemoglobin (HbA1c).Methods: Data were collected fr...